Accuray Reports Fiscal 2026 Results Amid Strategic Transformation
Accuray Incorporated ended its 2026 fiscal year with a net loss of $49.2 million, as the medical technology company navigated volatile international markets and geopolitical headwinds. Despite the bottom-line contraction, leadership emphasized that aggressive cost-cutting measures and a new financing deal have fortified the firm's operational foundation for the year ahead.
For the fourth quarter, total net revenue reached $100.9 million, representing a 21 percent decline compared to the same period last year. The drop was driven primarily by a 42 percent slump in product revenue, which totaled $40.8 million. However, the company’s service business provided a buffer, climbing 6 percent to $60.1 million, signaling continued demand for the company’s long-term maintenance and software support.
CEO Steve LaNeve characterized the year as a period of structural change. The company successfully executed a transformation plan that delivered over $20 million in cost and margin improvements, significantly outpacing its initial $12 million target. To bolster its balance sheet, Accuray secured a comprehensive financing agreement with TCW Asset Management, which provides necessary liquidity and covenant relief through December 2027.
While the company enters fiscal 2027 with a stronger internal focus, management declined to provide formal revenue or EBITDA guidance. Citing ongoing macroeconomic uncertainty and tariff pressures in key regions like China and the Middle East, leadership stated that the current priority remains maintaining discipline and leveraging strategic partnerships to drive sustainable growth.
Comments (0)
No comments yet. Be the first!